Skip to content

Family and Social Services Administration

< Back | Agency Home | Submit Events >

Search events. View events.
  Family and Social Services Administration Submit Events
Welcome to the IN.gov Calendar. Please use the Help button to the right for any assistance while using the Calendar.
Click for help in using calendar displays. Print the contents of the current screen.

Advanced Search (New Search)
  From:
  To:

 

 

 


Submit
Entry Details
Notify me if this event changes.Add this event to my personal calendar.Email this entry to a friend.
Go Back
[FSSA] Therapeutics Committee Meeting
Start Date: 5/4/2012Start Time: 9:00 AM
End Date: 5/4/2012
This event recurs every 3 months on the first Friday until 11/2/2012.   Click here to see the series dates.
Entry Description

Meeting Agenda and Public Notification

Therapeutics Committee Meeting
Indiana Government Center South
Conference Center Room A

  1. Call to Order-Chair
  2. Opening Comments-OMPP
  3. Approval of Memoranda, Meetings of November 4, 2011
  4. Election of Officers, CY 2012
  5. Preferred Drug List: Therapeutic Class Re-Review
    1. Respiratory
      1. Antihistamine-Decongestant Combinations, 2nd Generation Antihistamines
      2. Antiviral Monoclonal Antibodies
      3. Beta Adrenergics and Corticosteroids
      4. Beta Agonists
      5. Bronchodilator Agents, Beta Adrenergic & Anticholinergic Combinations
      6. Leukotriene Receptor Antagonists
      7. Monoclonal Antibodies to Immunoglobulin E
      8. Nasal Antihistamines, Nasal Anti-inflammatory Steroids
      9. Oral Inhaled Glucocorticoids
      10. Phosphodiesterase-4 Inhibitors
      11. Pulmonary Antihypertensives – Phosphodiesterase Type 5 Inhibitors
    2. Anti-infectives
      1. Antivirals – Anti-herpetic
      2. Antivirals – Anti-influenza
      3. First- and Third-Generation Cephalosporins
      4. Fluoroquinolones
      5. Hepatitis C Agents
      6. Macrolides
      7. Ketolides
      8. Ophthalmic Antibiotics
      9. Oral Non-Systemic Antifungals
      10. Otic Antibiotics
      11. Systemic Antifungals
      12. Topical Antifungals
      13. Topical Antivirals
      14. Vaginal Antimicrobials
    3. Cardiovascular
      1. ACE Inhibitors
      2. ACE Inhibitors with CCBs
      3. ACE Inhibitors with Diuretics
      4. ARBs
      5. ARBs with CCBs
      6. ARBs with CCBs and Diuretics
      7. ARBs in combination with Diuretics
      8. Alpha-Beta Adrenergic Blockers
      9. Beta Adrenergic Blockers
      10. Beta Blockers with Diuretics
      11. Calcium Channel Blockers
      12. Calcium Channel Blocker with HMG CoA Reductase Inhibitors(Caduet)
      13. Direct Renin Inhibitors
      14. Direct Renin Inhibitors with ARBs
      15. Direct Renin Inhibitors with CCBs
      16. Direct Renin Inhibitors with CCBs and Diuretics
      17. Direct Renin Inhibitors with Diuretics
      18. Potassium Sparing Diuretics (Inspra)
    4. Lipotropics
      1. Bile Acid Sequestrants
      2. Fibric Acid Derivatives
      3. HMG CoA Reductase Inhibitors
      4. Lipotropics
    5. Antimigraine Preparations
    6. DPP4-HMG CoA Reductase Inhibitor Combinations
    7. Electrolyte Depleters
    8. MS Agents
    9. CNS and Others
      1. Antiemetics
      2. COX-II Inhibitors
      3. Narcotics
      4. Narcotic Antitussive/1st-generation Antihistamine Combinations
      5. NSAID and Prostaglandin Combination
      6. NSAID and Proton Pump Inhibitor Combination
      7. Skeletal Muscle Relaxants
      8. Smoking Deterrent Agents
    10. Dermatologic Agents
      1. Acne Agents
      2. Antipsoriatic Agents
    11. Endocrine
      1. Antidiabetic Agents, Oral
      2. Bone Resorption Inhibitors
      3. Forteo
      4. Growth Hormones
      5. Injectable Hypoglycemics, Insulin
      6. Injectable Hypoglycemics, Non-Insulin
    12. Gastrointestinal Agents
      1. Antiulcer Preparations
      2. H. Pylori Agents
      3. H2 Receptor Antagonists
      4. Laxatives and Cathartics
      5. Pancreatic Enzymes
      6. Proton Pump Inhibitors
      7. Ulcerative Colitis Agents
    13. Genitourinary Agents
      1. Benign Prostatic Hypertrophy Agents
      2. Urinary Tract Antispasmodics
    14. Hematologic Agents
      1. Direct Factor XA inhibitors (Xarelto)
      2. Direct Thrombin Inhibitor (Pradaxa)
      3. Hematinics
      4. Heparin and Related Products
      5. Leukocyte (WBC) Stimulants
      6. Platelet Aggregation Inhibitors
    15. Oral Contraceptives
    16. Prenatal Vitamins
    17. Targeted Immunomodulators
    18. Topical Agents
      1. Miotics-Intraocular Pressure Reducers
      2. Ophthalmic Antihistamines, Mast Cell Stabilizers
      3. Ophthalmic Anti-inflammatory Agents
      4. Ophthalmic Anti-inflammatory, Immunomodulator-Type (Restasis)
      5. Otic Preparations
      6. Topical Anti-inflammatory Agents-NSAIDs
      7. Topical Antiparasitics
      8. Topical Immunomodulators
      9. Topical Post Herpetic Neuralgia Agent (Lidoderm)
      10. Vaginal Estrogen Preparations
      11. Wound Care Products
  6. Post-launch analysis on claims utilization for Natroba
  7. Review of Synagis hospitalization data from October, November, and December 2011
  8. Public Comment
  9. Other Business
  10. Adjourn
Default
Entry Type:
Event
Entry Category:
  • Hearings
  • Meetings
  • IN.gov Category:
  • Family & Health
  • Agency Name
    Family and Social Services Administration

    Calendar software powered by Active Data Calendar   
    Select item(s) to Search








    Select item(s) to Search
    Select item(s) to Search

    Select item(s) to Search